Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common variations have confounded doctors and left anxious patients without guidance ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying ...

Followed categories will be added to My News. She has one of the most commonly inherited gene mutations – BRCA2 – which increases the risk of breast, ovarian and prostate cancers. Mia tested ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...